Know Cancer

or
forgot password

Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma


Phase 2
15 Years
65 Years
Open (Enrolling)
Both
Lymphoma

Thank you

Trial Information

Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma


- The feasibility will be evaluated in terms of objective response rate, efficacy of stem
cell collection, disease-free survival, and overall survival.


Inclusion Criteria:



- Patients who have refractory to first-line CHOP-like regimen

- Patients who have first relapse after

- first-line CHOP-like regimen

- upfront autologous or allogeneic hematopoietic stem cell transplantation

- Age 15 years or more

- ECOG performance status ≤ 2

- Adequate bone marrow function

- Adequate kidney,liver,cardiac

Exclusion Criteria:

- Patients who have received GEM or OX

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

objective response rate

Outcome Time Frame:

10/2009

Principal Investigator

Hawk Kim, professor

Investigator Role:

Principal Investigator

Investigator Affiliation:

Ulsan Universtity Hospital, ROK

Authority:

Korea: Food and Drug Administration

Study ID:

C-012A

NCT ID:

NCT00561301

Start Date:

November 2006

Completion Date:

October 2009

Related Keywords:

  • Lymphoma
  • Lymphoma

Name

Location